MedTrace Logo

Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease

NCT03299413 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-04-10

No results posted yet for this study

Summary

Scientists hypothesize that directly or parentally injecting Mesenchymal stem cells (MSCs) to affected areas will have a positive impact through reducing or abolishing intestinal inflammation in part via inhibition of neutrophil Myeloperoxidase (MPOx) activity. Inhibiting MPOx should modify disease progression as well as reduce colitis associated cancer risk.

Conditions

  • Inflammatory Bowel Diseases

Interventions

BIOLOGICAL

Wharton Jelly Mesenchymal stem cells

Wharton Jelly Mesenchymal stem cells will be injected intravenously

Sponsors & Collaborators

  • Scientific Research Support fund

    collaborator UNKNOWN

  • Hanan Jafar

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-05
Primary Completion
2019-11-30
Completion
2020-01-31

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03299413 on ClinicalTrials.gov